

Adult polycystic kidney disease

Renal artery stenosis

Tumours of the kidney and urinary tract

TUCOM

Dep. of Medicine

4th year

Dr. Hasan I. Sultan

22- 11- 2018


Adult polycystic kidney disease

Learning objectives:

1. Define adult polycystic kidney disease
2. Review pathogenesis of adult polycystic kidney disease
3. Recognize the clinical features of adult polycystic kidney disease
4. Outline the investigations of adult polycystic kidney disease
5. Outline the treatment of adult polycystic kidney disease


Adult polycystic kidney disease (APKD)

- ADPKD: It is an inherited multisystemic disease characterized by multiple cyst formation in both kidneys and other organs (like liver, pancreas or ovaries) with extrarenal noncystic manifestations such as mitral valve prolapse, intracranial aneurysms, and hernias.
- It is a common condition, with a prevalence of approximately 1 : 1000, and is inherited as an autosomal dominant trait. Small cysts lined by tubular epithelium develop from infancy or childhood and enlarge slowly and irregularly.
- Mutations in the PKD1 gene (chromosome 16) account for 85% of cases and PKD2 (chromosome 4) for about 15%.




ADPKD kidneys compared to a normal kidney


A




B



C



D



A to D, Steps involved in cyst formation: schematic of the sequence of events leading to renal cyst formation. Note that this process occurs hundreds or thousands of times during the natural history of polycystic kidney disease. ECM = extracellular matrix.

Clinical features

Common clinical features:

- Vague discomfort in loin or abdomen due to increasing mass of renal tissue
- Acute loin pain or renal colic due to haemorrhage into a cyst
- Hypertension
- Haematuria (with little or no proteinuria)
- Urinary tract or cyst infections
- Renal failure

Other clinical features:

- Hepatic cysts and hepatomegaly
- Cysts in other organs: pancreas, ovaries, lung and thyroid
- Berry aneurysms of cerebral vessels and subarachnoid haemorrhage
- Mitral and aortic regurgitation
- Colonic diverticula
- Abdominal wall hernias

Investigations

The diagnosis is usually based on family history, clinical findings and ultrasound examination.

- Ultrasound examination demonstrates cysts in both kidneys in approximately 95% of patients over the age of 20 years and 100% of patients over 30 years. U/S is the screening method of choice.
- Cysts may also be identified by other imaging modalities, such as MRI
- Mutation screening of PKD1 or PKD2 but this is seldom used in routine clinical practice.
- Screening for intracranial aneurysms is not generally indicated but can be done by MR angiography in families with a history of subarachnoid haemorrhage.



MRI images of the kidneys. A Normal kidneys. B Polycystic kidneys: although the kidney enlargement is extreme.

Management

- Good control of blood pressure is important, by angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers to achieve a target blood pressure of less than 125/75 mm Hg.
- Treatment of urinary tract infection and nephrolithiasis
- The vasopressin V2 receptor antagonist tolvaptan may retard kidney volume increase and slow the rate of GFR decline.
- Patients with APKD are usually good candidates for dialysis and transplantation.
- Surgery removing one or both kidneys to make space for a renal transplant or when it a source of pain or infection.

Prognosis

ESRD develops in approximately 50% of patients with ADPKD by 60 years of age.

Renal artery stenosis

Learning objectives:


1. Define renal artery stenosis
2. Recognize the types and pathophysiology of renal artery stenosis
3. Outline the clinical features of renal artery stenosis
4. Review the investigations of renal artery stenosis
5. Review the treatment of renal artery stenosis

Renal artery stenosis

Renal artery stenosis is a relatively uncommon disorder, which presents clinically with hypertension. It has been estimated to occur in about 2% of unselected patients with hypertension.


There are two types of renal artery stenosis:

- **Atherosclerotic type:** is the most common cause (90% of patients). More common in old men, smokers and diabetics. Associated with atherosclerosis of the aorta and other major branches, coronary, cerebral or other vascular disease.
- **Fibromuscular dysplasia type (10% of patients):** is characterised by hypertrophy of the media (medial fibroplasia), which narrows the artery, but rarely leads to total occlusion. It most commonly presents with hypertension in young women.



Pathophysiology;

- Renal artery stenosis results in a reduction in renal perfusion pressure, which activates the renin–angiotensin system, leading to increased circulating levels of angiotensin II. This provokes vasoconstriction and increases aldosterone production by the adrenal, causing sodium retention by the renal tubules.
- Significant reduction of renal blood flow occurs when there is greater than 70% narrowing of the artery



Presentation and clinical features of renal artery stenosis

Renal artery stenosis is more likely if:

1. Hypertension is severe, of recent onset or difficult to control
2. Kidneys are asymmetrical in size
3. Flash pulmonary oedema occurs repeatedly*
4. There is peripheral vascular disease of the lower limbs
5. There is renal impairment*
6. Renal function has deteriorated on ACE inhibitors or angiotensin II receptor blockers


*** Particularly with bilateral disease.**


Investigations:

- Imaging of the renal vasculature with either CT angiography or MR angiography should be performed to confirm the diagnosis
- Biochemical testing may reveal impaired renal function and an elevated plasma renin activity, sometimes with hypokalaemia due to hyperaldosteronism.
- Ultrasound may also reveal a discrepancy in size between the two kidneys.

Renal artery stenosis

“Multiphase CT of the renal tract demonstrates an atrophic right kidney with a delayed nephrogram, with only the tip of the upper pole enhancing





MRA showed a high-grade stenosis of the proximal right renal artery. The right kidney was markedly smaller but smoothly margined. Parenchymal enhancement of the right kidney was delayed.

Management:

- **Atherosclerotic disease:** The first-line management is medical therapy with intensive lipid lowering, use of aspirin, smoking cessation, and control of hypertension and diabetes mellitus. Angioplasty and stenting is now rarely performed in atherosclerotic disease, because there are risks of renal artery occlusion, renal infarction, and atheroemboli.
- **Fibromuscular dysplasia:** Pharmacologic treatment to control hypertension. Intervention with angioplasty (with or without stenting) or surgery should be considered for patients with severe or difficult to control hypertension or declining kidney function with high chance of success in improving blood pressure and protecting renal function.

Tumours of the renal system

Learning objectives:

1. Recognize the common forms of tumour of renal system including: Renal adenocarcinoma, urothelial tumours and prostate cancer.
2. Identify the risk factors op of renal system tumours
3. Clarify the clinical features of renal system tumours
4. Review the investigations of renal system tumours
5. Review the treatment of renal system tumours

Tumours of the kidney and urinary tract

1- Renal adenocarcinoma

Renal adenocarcinoma is by far the most common malignant tumour of the kidney in adults. It is twice as common in males as in females. The peak incidence is between 65 and 75 years.

The tumour arises from renal tubular cells.

Microscopically, clear cell carcinomas are the most common histological subtype (85%), with papillary, chromophobe and collecting duct tumours making up the remaining 15%.

Clinical features:

- 50% of patients are asymptomatic and identified incidentally.
- 60% present with haematuria
- 40% with loin pain
- 25% with a mass
- 10% present with a triad of pain, haematuria and a mass.
- Systemic effects; including fever, raised ESR, polycythaemia, disorders of coagulation, hypercalcaemia, and abnormalities of plasma proteins and liver function tests, due to secretion of products by the tumour, such as renin, erythropoietin, PTH-related protein (PTHrP) and gonadotrophins.

A**B**

Renal adenocarcinoma. A- In this CT, the right kidney is expanded by a low-density tumour, which fails to take up contrast material. Tumour is shown extending into the renal vein and inferior vena cava (arrow). B- Pathology specimen showing typical necrosis.

Investigations:

- Ultrasound is the investigation of first choice and allows differentiation between solid tumour and simple renal cysts.
- If the results are suggestive of a tumour, contrast enhanced CT of the abdomen and chest should be performed for staging.
- If the nature of the lesion is uncertain, ultrasound or CT-guided biopsy may be used to avoid nephrectomy for benign disease.

Management:

- Radical nephrectomy that includes the perirenal fascial envelope and ipsilateral para-aortic lymph nodes is the treatment of choice.

- Surgery may also play a role in the treatment of solitary metastases, since these can remain single for long periods and excision may be worthwhile.
- Renal adenocarcinoma is resistant to most chemotherapeutic agents, but recently, two new classes of drugs are now the mainstay of therapy. These are:
 - Tyrosine kinase inhibitors: sunitinib and pazopanib.
 - Mammalian target of rapamycin (mTOR) inhibitors: temsirolimus and everolimus.

Prognosis: If the tumour is confined to the kidney, 5-year survival is 75%, but this falls to 5% when there are distant metastases.

2- Urothelial tumours

- Tumours arising from the transitional epithelium of the renal tract can affect the renal pelvis, ureter, bladder or urethra. The bladder is by far the most frequently affected site.
- Almost all tumours are transitional cell carcinomas, but squamous carcinoma may occur in urothelium that has undergone metaplasia, usually following chronic inflammation or irritation due to stones or schistosomiasis.
- **Risk factors:** include cigarette smoking and exposure to industrial carcinogens like aromatic amines, aniline dyes and aldehydes. Chronic inflammatory processes, such as schistosomiasis and chronic bladder stones, predispose to squamous carcinomas by causing squamous metaplasia.

Clinical features:

More than 80% of patients present with painless, visible haematuria. Usually affecting males above 40 years.

Note: painless frank hematuria suggestive of urinary tract tumors until prove otherwise.

Investigations:

- Cystoscopy (usually flexible cystoscopy under a local anaesthesia).
- Imaging of the upper urinary tract (CT urogram is the gold standard but IVU and renal ultrasound are also acceptable).
- CT of the abdomen, pelvis and chest for staging.

Management:

- Most bladder tumours are low-grade superficial lesions that can be successfully treated by:
 - Endoscopically, transurethral resection of the tumour.
 - Intravesical chemotherapy with mitomycin C.
 - Intravesical bacille Calmette–Guérin (BCG) treatment.
- The management of invasive bladder tumours involves radical cystectomy with urinary diversion into an incontinent ileal conduit.

The prognosis of bladder tumours depends on tumour stage and grade.

3- Prostate cancer

Prostate cancer is the most common malignancy in men in the UK, with a prevalence of 105 per 100 000 population, and almost all are adenocarcinomas. The mean age of presentation is 70 years.

Clinical features:

- Most patients either are asymptomatic or present with lower urinary tract symptoms indistinguishable from benign prostatic enlargement: slow flow, hesitancy, incomplete emptying, dribbling after micturition, frequency, nocturia and palpable bladder.
- On digital rectal examination (DRE), the prostate may feel nodular and stony hard, and the median sulcus may be lost.
- Symptoms and signs due to metastases are much less common, which may include back pain, weight loss, anaemia and obstruction of the ureters.

Investigations:

- Measurement of serum prostate specific antigen (PSA) level, together with DRE, is the cornerstone of diagnosis.
- Individuals suspected of having prostate cancer, based on an elevated PSA and/or abnormal DRE, should undergo transrectal ultrasound-guided prostate biopsies.
- If the diagnosis of prostate cancer is confirmed, staging should be performed by pelvic MRI to assess the presence and extent of local involvement.
- An isotope bone scan should be carried out if distant metastases are suspected

Management:

1- Tumour confined to the prostate is potentially curable by radical prostatectomy, radical radiotherapy or brachytherapy (implantation of small radioactive particles into the prostate).

2- Metastatic prostate cancer is treated by androgen depletion, which may prevent tumour cell growth:

- ☐ **Surgery: castration (orchidectomy) or**
- ☐ **More commonly, androgen-suppressing drugs:**
 - **Androgen receptor blockers, such as bicalutamide or cyproterone acetate.**
 - **Gonadotrophin-releasing hormone (GnRH) analogues, such as goserelin, continuously occupy pituitary receptors, preventing them from responding to the GnRH pulses that normally stimulate luteinising hormone (LH) and follicle-stimulating hormone (FSH) release. This initially causes an increase in testosterone before producing a prolonged reduction, and for this reason the initial dose must be covered with an androgen receptor blocker to prevent a tumour flare.**

3- Failure of hormonal therapy:

- **Chemotherapy with docetaxel can then be effective and provide a modest (around 3 months) survival advantage.**
- **Radiotherapy is useful for localised bone pain**
- **Pain control by analgesia.**

Prognosis: the 10-year survival rate of patients with tumours localised to the prostate is 95%, but if metastases are present, this falls to 10%.

Thanks